The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
about
Liver flukes: the malady neglectedThe tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancerDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaThe significance of genetics for cholangiocarcinoma developmentCholangiocarcinomaCholangiocarcinoma: Current Knowledge and New DevelopmentsA proteomic analysis of human bileManagement of perihilar cholangiocarcinoma in the era of multimodal therapyClassification, diagnosis, and management of cholangiocarcinomaIgG4-Associated Cholangitis Can Mimic Hilar Cholangiocarcinoma.Liver masses: a clinical, radiologic, and pathologic perspective.Diagnosis of cholangiocarcinoma.Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies.C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinomaGuidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.Risk factors for Opisthorchis viverrini and minute intestinal fluke infections in Lao PDR, 2009-2011.Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures.Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines.Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinomaExpression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma.New insights on cholangiocarcinoma.Factors associated with serum CA19-9 levels among healthy children: a cross-sectional study.Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopyDiagnostic approaches for cholangiocarcinoma.Clinical diagnosis and staging of cholangiocarcinomaPathogenesis, diagnosis, and management of cholangiocarcinomaSerum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinomaHepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection.A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinomaPatients, cells, and organelles: the intersection of science and serendipity.Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial HospitalImaging of malignancies of the biliary tract- an update.Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach.A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.Perioperative Management of Hilar Cholangiocarcinoma.
P2860
Q24598799-8AF3FE85-9B76-4DF2-BCCC-719CFD7182AEQ24612587-221BF2CD-0DC7-44C9-9D3C-A625BF946213Q26767120-5184F2BA-4C2A-4F02-8FB9-9A84E755012DQ26784091-BA468F17-956E-49A8-950C-8F3FC797B27BQ26865749-8EFA5908-5B42-412C-ACE8-B97B571D7522Q27001694-DD20EABA-406C-45F9-ACCA-87714D73CD7CQ28076098-1A5C65FB-0C46-459F-99E5-75C2AE61846DQ28256550-61B740CB-B5B4-4353-B713-4BC2D1CCA3CDQ28273788-B8C6640A-DA7B-46EE-94D0-66EC7CA2EDB0Q28275153-F3DD680E-A9D1-42CE-8E94-BB2EAA20A4FAQ30279247-BC239EAF-AC57-4752-B6B8-3519F6AEC71AQ30403670-9E793957-3A73-4DCD-ACD6-27546B09D32CQ30493559-1141D520-DFE3-4893-A786-0DBAE122219AQ30585821-F9A19D6A-2F49-48E9-B4C6-8AD9060F9173Q33437197-E3C8C3AE-2F69-4BD7-AD42-0176C6FF70E4Q33679691-6FEB3706-3902-4F62-8219-6BE912486117Q33869507-5FF2CDE6-6070-4EED-A26C-7F24814B3CCBQ33961881-B001ED09-3080-42E9-A32F-84DD236C4F94Q34015996-05C3E7DA-4078-4E55-BD9F-50B222FE7922Q34027102-3C099312-6C02-4DB4-B4AC-0C7570A7EC21Q34127295-665D834F-F0EB-4C05-814F-23DDDE5E0231Q34183196-310D5EA2-689D-4B83-A9B5-BC8C4863EBD6Q34382675-D50E2D9F-11F0-4298-8A48-75D59950189BQ34391135-07BB68B4-60BB-4436-A5CA-86581ED4BFAAQ34498630-FD1597C3-BE68-438E-9519-88024176A9EAQ34528218-8EFC2BA1-4FDB-465D-888D-30049ACFBDE2Q34594430-529F80A2-A420-46FB-8567-399A56143523Q34631337-1F92657E-15DE-4444-B2A1-6C6786B655DEQ34656747-0BE41289-457F-4557-AE74-BFD75F9D2B4BQ34660116-E9C7FEC6-1F7E-43F3-A87D-0E467D5BE72BQ34732888-761D9E37-18AE-435F-9527-45B90C9CD4ECQ34744836-DEA6F07F-DD3E-47DE-9246-C28812A4BC81Q34836574-58525E1F-3B18-48FF-86FA-9D5B5EC080F0Q34860483-2FBDF3E2-F128-4B26-8230-21201D5F5FB3Q35011076-F4345EE6-EFAA-4E5F-A383-9FA61EB7680BQ35093239-03D7EB20-FE69-426B-8658-291D593DFDE0Q35585581-3F04D25F-604F-4E2F-BFF0-833330CCD0C9Q35594611-E0EA3DCD-71B3-47B9-9D31-D319D95F1FC2Q35620650-F98C9549-BAD6-4317-A944-60567A5C5583Q35645739-2156E04B-300D-4A32-845A-42977092415D
P2860
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@ast
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@en
type
label
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@ast
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@en
prefLabel
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@ast
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@en
P2093
P921
P1476
The utility of CA 19-9 in the ...... rimary sclerosing cholangitis.
@en
P2093
P304
P356
10.1111/J.1572-0241.2000.01685.X
P407
P577
2000-01-01T00:00:00Z